Pre-seed Strategic Partnerships with academic centers of excellence and strategic or financial investors build the core of our BRIDGE initiatives. Since 2016, Evotec has initiated and advanced the following partnerships:

In September 2023, it was announced that Evotec and Novo Nordisk have launched LAB eN², a translational BRIDGE partnership with a cohort of US East Coast research institutions, including Harvard University, Yale University, Mass General Brigham, and Beth Israel Deaconess Medical Center LAB eN² will combine Evotec’s multimodality drug discovery and development capabilities with Novo Nordisk’s therapeutic, clinical and commercial expertise to advance several early-stage research within cardiometabolic diseases and rare blood and endocrine disorders.

In September 2023, it was announced that Evotec has entered into a new BRIDGE partnership – 65LAB – to advance early-stage therapeutic opportunities arising from Singapore academic research institutions. 65LAB is funded by leading investors with a specific interest in creating new companies in the Singapore ecosystem; Clavyst Bio, Polaris Partners, Lightstone Ventures and Leaps by Bayer. Launching with the National University of Singapore and Duke-NUS Medical School, 65LAB will expand to include other high quality research institutions in the region.

In June 2021, Evotec and CEBINA GmbH, a Central European Biotech Incubator and Accelerator, announced the launch of Danube Labs, a partnership between to fast-track early-stage academic research from Central and Eastern European academic institutions towards the discovery and development of new therapeutics. Financed by a group of private investors, Danube Labs will progress funded projects to a stage at which new companies can be created.

In May 2021, Evotec announced the launch of beLAB1407 in collaboration with Bristol Myers Squibb. beLAB1407 is an academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from a group of top-tier UK academic institutions.

In April 2021, Evotec announced the launch of beLAB2122, a translational BRIDGE in collaboration with Bristol Myers Squibb. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

In September 2017, Evotec and Toronto Innovation Acceleration Partners (TIAP) announced the launch of LAB150, a transformational Toronto-based partnership giving Canadian academic institutions and teaching hospitals access to the world-class infrastructure and drug discovery expertise of Evotec. In October 2022, Amgen joined LAB150 as a strategic partner and investor.

In November 2016, Evotec announced a novel strategic partnership with the University of Oxford, Oxford University Innovation and Oxford Sciences Innovation (now Oxford Science Enterprises), aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Today, 38 projects across multiple therapeutic areas and modalities have been funded and a first company, Dark Blue Therapeutics, has been spun out.